Tirzepatide vs Semaglutide: How a Physician Chooses Between Them

Tirzepatide and semaglutide are the two prescription medications most patients ask about when they come in for medical weight loss. Both are given as a once weekly injection, both work on appetite and the way the body handles glucose, and both have produced weight loss in clinical trials that older medications never approached. They are not interchangeable, and the choice between them is a medical decision rather than a preference.

The direct answer: tirzepatide acts on two gut hormone receptors and produced more weight loss on average in the trials, while semaglutide acts on one and has a longer track record with specific cardiovascular data. Which one is right for you depends on your health history, blood work, tolerance and goals, and at Vital Medical Care & Aesthetics that decision is made by Dr. Joelle Vital, MD at a consultation before tirzepatide or semaglutide is prescribed.

Both are weekly GLP 1 based medications, and tirzepatide adds a second hormone

Semaglutide is a GLP 1 receptor agonist. It mimics glucagon like peptide 1, a hormone the gut releases after a meal, which slows stomach emptying, increases insulin release when glucose is high and acts on appetite centers in the brain. The result for most patients is that they feel full sooner, stay full longer and think about food less.

Tirzepatide does the same and also activates the GIP receptor, for glucose dependent insulinotropic polypeptide, a second gut hormone. The combination appears to produce a stronger effect on appetite and on how the body stores and uses energy, which is the likely reason for the larger average weight loss seen in trials. Both are prescription medications, both are started at a low dose and increased in steps by the physician over several months, and both require follow up.

Neither is a standalone fix. In the clinic they are prescribed within a physician supervised medical weight loss plan that includes nutrition, activity and regular review.

What the clinical trials showed

The numbers below are average results from the large trials that led to approval, in adults with obesity or overweight who also followed a diet and activity program. They are trial ranges, not a promise, and individual results vary widely in both directions.

Measure	Semaglutide	Tirzepatide
Mechanism	GLP 1 receptor agonist	GLP 1 and GIP receptor agonist
Dosing	Once weekly injection	Once weekly injection
Average weight loss, pivotal trial	About 15 percent of body weight at 68 weeks	About 15 to 21 percent at 72 weeks, depending on dose
Placebo in the same trials	About 2 to 3 percent	About 3 percent
Head to head trial, 2025	About 14 percent at 72 weeks	About 20 percent at 72 weeks
Time to reach full dose	Roughly 4 to 5 months	Roughly 5 months

A head to head trial published in 2025 in the New England Journal of Medicine compared the two directly in adults without diabetes and found tirzepatide produced greater average weight loss. That gap is real but it describes averages. Plenty of patients lose a large amount on semaglutide, and some patients tolerate it better than tirzepatide.

Side effects: similar in kind, somewhat different in frequency

Both medications share the same main side effects, because both slow the stomach: nausea, diarrhea, constipation, vomiting, bloating and reflux. These are most common during the first weeks after each dose increase and tend to ease as the body adjusts. Our post on whether semaglutide causes hair loss covers one more effect patients ask about.

In the pivotal trials nausea was reported by roughly 40 to 45 percent of semaglutide patients and about 25 to 35 percent of tirzepatide patients, with similar rates of diarrhea. Discontinuation because of side effects was in the single digits for both. Our post on tirzepatide side effects and supervised dosing covers how slower escalation reduces them.

The serious risks both share

• A boxed warning for thyroid C cell tumors seen in rodent studies. Neither is prescribed to anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
• Pancreatitis, which is uncommon but requires stopping the medication and being assessed.
• Gallbladder disease, more likely with rapid weight loss.
• Dehydration and kidney strain from prolonged vomiting or diarrhea.
• Delayed stomach emptying, which matters before anesthesia and with some other medications.

Neither is used in pregnancy or while breastfeeding, and both are stopped well before a planned pregnancy.

How the physician chooses: six factors

At the consultation the decision comes down to a short list of questions, answered with your history and your blood work in hand.

1. How much weight needs to come off. A larger goal tilts toward tirzepatide, given the trial averages. A modest goal can be met with either.
2. Blood sugar. Both help, but a patient with prediabetes or type 2 diabetes may have one favored over the other based on A1c and other medications.
3. Heart history. Semaglutide has trial data showing a reduction in major cardiovascular events in people with established heart disease, which can favor it for those patients.
4. Gut tolerance. A history of reflux, gastroparesis or a sensitive stomach may favor the medication with the lower nausea rate, or a slower escalation on either.
5. Prior response. Patients who plateaued on semaglutide are sometimes switched to tirzepatide, and the reverse happens when tirzepatide is not tolerated.
6. Access. Insurance coverage, supply and the patient’s budget are practical realities, and the physician discusses them openly. Pricing is confirmed at the consultation and the price guide lists what the clinic offers.

Brand name products and compounded versions both exist. The physician decides what is appropriate for each patient and what will be prescribed. Dosing is set and adjusted by the physician at follow up visits, never by the patient.

Who should not take either, and what blood work is for

Neither medication is prescribed without a consultation, and some patients are told at that visit that another approach is safer. The clear exclusions are a personal or family history of medullary thyroid cancer or MEN 2, pregnancy or breastfeeding, and a known serious allergy to the medication. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease or diabetic eye disease calls for caution and sometimes a different plan.

Blood work is where indicated before starting, and it serves three purposes. It checks for conditions that change the choice, such as thyroid or kidney problems and blood sugar status. It gives a baseline for lipids and liver function so change can be measured. And it can turn up reasons for weight gain that a medication will not fix, such as thyroid disease, which our post on not losing weight on tirzepatide discusses.

Patients also need to tell the physician about every medication they take, since both drugs slow stomach emptying and can change the absorption of oral medications, and about any planned surgery.

Switching between them

Switching is common and safe when it is managed by the physician. The usual reasons are a plateau on one medication, side effects that do not settle, or a change in supply or coverage. The switch is not a straight swap at the same dose. The physician chooses a starting point on the new medication based on where you were on the old one and how you tolerated it, then escalates from there.

Expect some return of mild nausea during the first weeks on the new medication, and expect the weight curve to pause briefly before it moves again. Switching does not undo progress, and most patients who change for a good reason report that the second medication suits them better.

Starting medical weight loss in Merrick

The first step is a consultation, not a prescription. Dr. Vital reviews your history, orders blood work where indicated, discusses both medications and recommends one, with the dose schedule and follow up visits set at that point. The clinic also offers a three month medical weight loss program that builds the medication into a supervised plan. Patients who also have Botox here can read what to avoid after Botox before that visit.

Vital Medical Care & Aesthetics is at 2209 Merrick Rd, Suite 202, Merrick, NY 11566, about a ten minute walk from the Merrick LIRR station on the Babylon Branch, with the NICE n19 bus along Merrick Road. Hours are Monday 9am to 5pm, Tuesday 9am to 7pm, Wednesday and Thursday 7:30am to 5pm, Friday 9am to 5pm and Saturday 9am to 2pm. Visits are by appointment: book a tirzepatide consultation online or call (516) 414-1101.

Questions readers ask

Read next

• Side Effects of Tirzepatide and How Supervised Dosing Reduces Them
• Not Losing Weight on Tirzepatide? Six Things We Check First
• Does Semaglutide Cause Hair Loss? What the Evidence Shows